3 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,606 as of Thursday, May 8, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,938 issues advancing vs. 1,065 declining with 159 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Merck ( MRK), down 1.3%, Valeant Pharmaceuticals International ( VRX), down 0.9%, Actavis ( ACT), down 0.9% and Allergan ( AGN), down 0.6%. Top gainers within the industry include Biogen Idec ( BIIB), up 2.0%, Alexion Pharmaceuticals ( ALXN), up 1.5% and Regeneron Pharmaceuticals ( REGN), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novo Nordisk A/S is down $0.52 (-1.2%) to $43.00 on average volume. Thus far, 616,202 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $42.99-$43.32 after having opened the day at $43.17 as compared to the previous trading day's close of $43.51.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $121.2 billion and is part of the health care sector. Shares are up 17.8% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday